Article thumbnail

Synthesis of 4′,7-Diacetoxyapigenin and Its Apoptotic Induction in Human Hep G2 Cells

By Keyong Xu, Feng Liu, Benguo Liu, Han Gao and Zhengxiang Ning

Abstract

In this study, 4′,7-diacetoxyapigenin [4-(7-acetoxy-5-hydroxy-4-oxo-4H-chromen-2-yl) phenyl acetate] was synthesized for the first time. Its chemical structure was identified by UV, ESI-MS, 1H and 13C-NMR. It could inhibit the proliferation of Hep G2 cells in a dose-dependent manner and induce the significant increase of the G0/G1 cell population. After treatment by 4′,7-diacetoxyapigenin, phosphatidylserine of Hep G2 cells could significantly translocate to the surface of the membrane. The increase of an early apoptotic population was observed by both annexin-FITC and PI staining. It was concluded that 4′,7-diacetoxyapigenin not only induced cells to enter into apoptosis, but also affected the progress of the cell cycle

Topics: Communication
Publisher: Molecular Diversity Preservation International (MDPI)
OAI identifier: oai:pubmedcentral.nih.gov:2885088
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2006). Anti-Proliferative effect of apigenin and its apoptotic induction in human Hep G2 cells. Cancer Lett.
  2. (1997). Apoptosis by death factor. Cell
  3. (1997). Apoptosis in the liver and its role in hepatocarcinogenesis.
  4. (1995). Apoptosis in the pathogenesis and treatment of disease. Science
  5. (1995). Cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev.
  6. (1991). Potential role of tamoxifen in prevention of breast cancer.
  7. (1994). Programmed cell death (apoptosis) and response to anti-cancer drugs. Anticancer Drugs
  8. (1997). Programmed cell death in animal development. Cell
  9. (1998). Proteolytic activities that mediate apoptosis.
  10. (2000). The hallmarks of cancer. Cell
  11. (1998). The role of apoptosis in the pathogenesis, prognosis, and therapy of hematologic malignancies. Leukemia